[Topical optical beta-adrenergic antagonists and quinidine--a risky combination].
Pianka
P
P
Lazar
M
M
Geyer
O
O
D000287:Administration, Topical; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D004336:Drug Antagonism; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D009883:Ophthalmic Solutions; D011802:Quinidine / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D013999:Timolol / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D013999:Timolol; D011802:Quinidine